The Secretion of Growth Regulatory Molecules by PC13 Embryonal Carcinoma Cells
PC13 embryonal carcinoma (EC) is a malignant teratocarcinoma cell line derived from the early postimplantation mouse embryo. PC13 EC cells may be induced, by treatment with retinoic acid (RA), to undergo differentiation in vitro into a benign cell type, PC13 END, which phenotypically resembles the visceral endoderm of the early postimplantation mouse embryo (1,2). There is a pronounced change in growth regulatory properties associated with this differentiation step. Serum free culture conditions have been developed which will support the multiplication of PC13 EC cells in vitro. The medium, termed ECM, comprises transferrin (5 μg.ml.), human low density lipoprotein (LDL, 50 μg.ml.) and human high density lipoprotein (HDL, 50 μg.ml.) in a basal medium of MCDB104:DME (1:1). The medium does not contain deliberately added growth factors. PC13 END cells will survive in this medium, but their proliferation is dependent upon exogenous growth factors, such as epidermal growth factor (EGF) or insulin (3,4). The susceptibility of PC13 END cells to the action of these hormones is partially due to the appearance of specific cell surface receptors upon differentiation (3,4). It is thus clear that PC13 EC cell proliferation is regulated in a different fashion to PC13 END.
KeywordsEpidermal Growth Factor Embryonal Carcinoma Embryonal Carcinoma Cell Visceral Endoderm Exogenous Growth Factor
Unable to display preview. Download preview PDF.
- 1).Adamson, E.D., et al., Cell 17: 469–476Google Scholar
- 2).Rayner, M. and Graham, C.F., J. Cell Sci. in the press.Google Scholar
- 3).Rees, A. et al., Nature 281: 309–311Google Scholar
- 4).Heath, J., et al.,. J. Cell Biol. 91: 293–297Google Scholar
- 5).DeLarco, J. and Todaro, G. P.N.A.S. 75: 4001–4005.Google Scholar